Usted buscó: laboratorieavvikelser (Sueco - Inglés)

laboratorieavvikelser
laboratory abnormalities

och laboratorieavvikelser
multiple multiple sclerosis sclerosis (european (north study) american study)

andra laboratorieavvikelser
other laboratory abnormalities

(benefit) laboratorieavvikelser
american study)

(benefit) # laboratorieavvikelser
betaferon 250 microgram

biverkning och laboratorieavvikelser
adverse event and laboratory abnormalities

utvalda behandlingsutlösta laboratorieavvikelser
selected treatment emergent laboratory abnormalities

laboratorieavvikelser associeras med användningen av interferoner.
laboratory abnormalities are associated with the use of interferons.

hematologiska laboratorieavvikelser av ctc- grad 3/ 4 i kliniska prövningar
ctc grades 3/ 4 haematological laboratory abnormalities in clinical studies

laboratorieavvikelser som betraktas som biverkningar finns upptagna i ett textavsnitt nedanför tabellen.
laboratory abnormalities considered adrs are included in a paragraph below the table.

laboratorieavvikelser som betraktas som biverkningar finns upptagna i ett textavsnitt nedanför tabell 2.
laboratory abnormalities considered adrs are included in a paragraph below table 2.

en patient fick läkemedelsrelaterade laboratorieavvikelser, asat grad 4 och alat grad 3, vilka betraktades som allvarliga.
one patient experienced drug related laboratory abnormalities, grade 4 ast and grade 3 alt, which were considered serious.

behandlingen med dutrebis ska omedelbart sättas ut vid kliniska tecken, symtom eller laboratorieavvikelser som tyder på pankreatit.
treatment with dutrebis should be stopped immediately if clinical signs, symptoms or laboratory abnormalities suggestive of pancreatitis occur.

behandlingsrelaterade laboratorieavvikelser för amylas och lipas har observerats hos patienter som behandlats med simeprevir i kombination med sofosbuvir (tabell 6).
treatment-emergent laboratory abnormalities in amylase and lipase have been observed in patients treated with simeprevir in combination with sofosbuvir (table 6).

biverkningaroch laboratorieavvikelser med incidenser ≥10% och respektive incidens med placebo; signifikant associerade biverkningar < 10%
adverse events and laboratory abnormalities with incidence rates ≥ 10% and the respective percentages under placebo; significantly associated side effects < 10%

rapporterade kliniska biverkningar och laboratorieavvikelser hos samtliga vuxna patienter behandlade med cancidas (totalt 989) var generellt milda och ledde sällan till avbrott.
19 reported clinical and laboratory abnormalities among all adult patients treated with cancidas (total 989) were typically mild and rarely led to discontinuation.

avvikelser i laboratorievärden i kontrollerade kliniska studier var laboratorieavvikelser relaterade till ziagen- behandling ovanliga och inga skillnader i incidens noterades mellan patienterna i ziagen - och kontrollgrupperna.
laboratory abnormalities in controlled clinical studies laboratory abnormalities related to ziagen treatment were uncommon, with no differences in incidence observed between ziagen treated patients and the control arms.

kliniskt signifikanta laboratorieavvikelser inträffade frekvent (≥ 5%) inklusive ökning i alkaliskt fosfatas, asat och bilirubin vilka ansågs vara relaterade till den underliggande sjukdomen och inte till caelyx.
clinically significant laboratory abnormalities frequently (≥ 5%) occurred including increases in alkaline phosphatase; ast and bilirubin which were believed to be related to the underlying disease and not caelyx.

tabell 1 (biverkningaroch laboratorieavvikelser med incidenser ≥ 10% och respektive incidens med placebo; signifikant associerade biverkningar < 10%)
23 table 1 (adverse events and laboratory abnormalities with incidence rates ≥ 10% and the respective percentages under placebo; significantly associated side effects < 10%).

i en subpopulation med 410 patienter med ovarialcancer inkluderade de kliniskt betydelsefulla laboratorieavvikelser som förekom i kliniska studier med caelyx en ökning av totalbilirubin (vanligtvis hos patienter med levermetastaser) (5 %) och serumkreatininnivåer (5 %).
in a subset of 410 patients with ovarian cancer, clinically significant laboratory abnormalities occurring in clinical trials with caelyx included increases in total bilirubin (usually in patients with liver metastases) (5%) and serum creatinine levels (5%).